Fact Sheet | Pricing

Part B International Drug Pricing Model for Medicare Part B Drugs

Fact Sheet | Pricing

Part B International Drug Pricing Model for Medicare Part B Drugs

The International Pricing Index (IPI) Model would initially focus on Part B single source drugs, biologicals, and biosimilars that encompass a high percentage of Part B drug utilization and spending. The CMS Innovation Center would test this model under section 1115A of the Social Security Act (the Act), which authorizes testing models expected to reduce program expenditures, while preserving or enhancing the quality of care furnished to beneficiaries. The model under consideration would include physicians, hospitals, and potentially other providers and suppliers in selected geographic areas.

Download the fact sheet


Related Articles | Pricing

How To | Chargemaster

8 tips to identify potential issues with the chargemaster

Reviewing billing edits and claim denials, as well as scheduling quarterly chargemaster reviews can help healthcare providers proactively identify potential challenges.

Trend | Payment Trends

Making price transparency easy for patients

Proactive providers are preparing for additional price transparency requirements to ensure they not only comply with government regulations, but also provide patients with enough information to make informed healthcare decisions.

News | Transparency

Supporters of releasing privately negotiated health plan rates dominate public comments

Supporters of a proposal for hospitals to release their health plan-negotiated rates, so far, have dominated comments on it to CMS.

Column | Payment, Reimbursement, and Managed Care

Why the call for price transparency is a call for innovation

To navigate and respond to the murky issue of price transparency, hospitals and health systems must innovate.